Develops drugs for cancer and desmoid tumors.
Jun 2026Revenue $0.00/yrExpenses $270M/yr
No trendCash runway ≈ 2.4 years from Jun 2026
Figures by year
When will Immunome be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $0.00 and expenses $270M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $6.94M | $231M | −$224M |
| Dec 2024 | $9.04M | $315M | −$306M |
| Dec 2023 | $14.0M | $124M | −$110M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.